An international effort has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder, homozygous familial hypercholesterolemia.
An international effort has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder, homozygous familial hypercholesterolemia.